Depression in Parkinson’s Disease by Hsieh, Shu-Haur
UCLA
UCLA Electronic Theses and Dissertations
Title
Depression in Parkinson’s Disease
Permalink
https://escholarship.org/uc/item/7rz5g40g
Author
Hsieh, Shu-Haur
Publication Date
2020
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
UNIVERSITY OF CALIFORNIA 
Los Angeles 
 
 
Depression in Parkinson’s Disease 
 
 
 
 
A thesis submitted in partial satisfaction 
of the requirements for the Master of Science 
in Epidemiology 
 
 
by 
 
 
Shu-Haur Hsieh 
 
 
2020 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by  
Shu-Haur Hsieh 
2020  
ii 
 
ABSTRACT OF THE THESIS 
 
Depression in Parkinson’s Disease 
 
by 
 
Shu-Haur Hsieh 
 
Master of Science in Epidemiology 
University of California, Los Angeles, 2020 
Professor Beate R. Ritz, Chair 
 
 Depression and anxiety are common mood disorders associated with Parkinson’s disease (PD). 
Among environmental factors, organophosphate (OPs) pesticide exposures have been previously 
linked to depression as well as to PD. Here we not only re-examine the relationship between 
depression and anxiety prior to PD onset, but for the first time are also considering whether OPs 
pesticide exposure modifies this association. From 2001 to 2015, we recruited 832 PD patients 
diagnosed early in the disease and 817 unaffected population controls from three counties in central 
California. We collected information about depression and anxiety diagnoses and psychotropic 
medication use prior to PD onset, and also generated ambient residential and/or the workplace 
address measures of OP pesticide exposures based on a geographic information system derived 
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agricultural pesticide exposure report system. Employing logistic regression models, we analyzed 
the association between depression/anxiety and PD adjusting for sex, age at diagnosis/interview, 
race, smoking, and education. Risk of PD was increased among those diagnosed with 
depression/anxiety and medication use prior to PD diagnosis (ORdepression & anxiety & medication use = 1.73, 
95% CI = 1.37-2.18), and the estimated effect sizes increased with depression/anxiety diagnoses 
being closer to the time of PD diagnosis, especially in males. While not formally statistically 
significant, OP exposures seemed to modify the size of the effect estimate for a depression/anxiety 
diagnosis and PD and the joint effects of depression/anxiety and OP pesticide exposures together 
were very large in males (ORFrequent exposure + Received depression and/or anxiety diagnosis = 5.00, 95%CI = 2.54-
9.87). 
These results further support the notion that depression and anxiety might be early symptoms 
in the prodromal phase of PD and that in males OP exposures may contribute to mood disorders 
prior to PD onset. 
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1. Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the U.S. 
and worldwide, and it is a complex disease with multiple causes (1). Previous research reported 
that the prevalence of depression and anxiety in PD patients is higher than in the general population 
(2, 3). For depression, the prevalence in PD patients varies from 2.7% to 90%, (weighted mean 
35%) (4), and for anxiety from 24.5% to 46.7% (weighted mean 31%) (5) compared with a 
prevalence of depression of 7.1%, and of anxiety of 19.1% among U.S. adults (6, 7). It has been 
proposed that deficits in the monoaminergic systems and changes in levels of inflammatory and 
neurotrophic molecules might contribute to these mood disorders in PD patients (8). 
Depression and anxiety may develop reactively as a response to the diagnosis of PD and fears 
about future disability or as a result of adverse life events (9, 10). However, here we are interested 
in identifying risk factors for depression in PD that is not reactive. Thus, we are only investigating 
depression and anxiety that occurred prior to a PD diagnosis. Previous studies stated that the loss 
of neurons in the dorsal raphe nuclei (DRN) that secrete serotonin and dysfunction of 
catecholamine (norepinephrine and dopamine) synthesized in locus coeruleus (LC) might be 
related to prodromal depression in PD (11). The LC and DRN are affected at Braak Stage 2, while 
the substantia nigra is affected only at Stage 3. It can explain the occurrence of depression before 
motor symptoms and diagnosis (12). 
Amongst environmental toxicants, organophosphate pesticides (OPs) have also been found 
to increase PD. OPs affect the nervous system is through inhibition of the acetylcholinesterase, an 
enzyme that hydrolyzes acetylcholine to cease cholinergic transmission, and this is a system also 
affected in PD (13, 14). In addition to inhibiting acetylcholinesterase, OPs may also contribute to 
PD risk because of their ability to enhance oxidative stress by increasing the production of reactive 
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oxygen species (15, 16). Inhibition of the acetylcholinesterase by OPs may cause depression 
because the inhibition of the acetylcholinesterase affects the balance of acetylcholine and 
dopamine (17). Chronic exposure to OPs may underlie psychological disorder through stimulating 
glutamatergic, dopaminergic, and serotonergic synaptic transmission by inhibition of the 
acetylcholinesterase (11). OPs may also regulate muscarinic Acetylcholine (ACh) receptor (18, 
19), and the upregulation and supersensitivity of the muscarinic ACh receptor is associate with 
depression (20). OPs may increase neurotransmitter serotonin (5-HT) release, down-regulating 5-
HT1A autoreceptor that increases the risk of mood disorder (21). Furthermore, the genetic 
susceptibility of paraoxonase (PON1) may also play a role in the relationship between OPs and 
depression (17). Slow PON1 metabolizing may lower the inactivate of OPs through hydrolysis and 
is associated with the development of depression (22, 23). 
We previously published a study that established an increased risk of PD with the prior 
occurrence of depression/anxiety in the first UCLA Parkinson’s Environment and Genes (PEG) 
study (2000-2010) (24). Since this publication, we doubled the PS case number in PEG, allowing 
us to, for the first time, efficiently examine effect measure modification by gender and OP pesticide 
exposures. 
 
2. Method 
This study is part of the PEG study, a population-based case-control study conducted in 
Fresno, Tulare, and Kern counties in California. All subjects have provided informed consent, and 
all procedures described in this study have been approved by the University of California, Los 
Angeles (UCLA), Institutional Review Board for human subjects. 
2.1 Study Population 
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 In this study, cases were recruited if they were current residents in one of three counties 
(Fresno, Tulare, or Kern) who had lived in California for five years or more, not too ill to 
participate, examined and diagnosed by a UCLA PEG study movement disorder specialists, and 
been diagnosed with PD within the past five years. Our diagnostic criteria for diagnosing clinically 
probable or possible PD have previously published (24, 25). The first wave of PD patients 
(diagnosed within three years of enrolment) were recruited from 2001 to 2007 through local 
neurology medical groups, medical centers, and the Veterans Affairs hospital. The second wave of 
PD cases (diagnosed within five years of enrolment) was recruited from 2011 to 2015 with the 
help of the California PD registry (CAPDR). For 1,167 initially (2001-2007) invited patients, 604 
were not eligible. From among 563 eligible, 90 were lost between screening and a mandatory clinic 
visiting, and 94 cases were excluded after the UCLA Movement disorder specialist established that 
they did not meet published criteria for idiopathic PD (26), leaving 379 cases. After excluding 
cases who provided incomplete information or were found not to have idiopathic PD at a follow-
up visit, 360 cases remained for study. From among 2,714 cases who were initially contacted from 
2011 to 2015, 1,980 were not eligible. From the remaining 734 cases, 85 cases refused to 
participate, 47 cases did follow an invitation for a physical examination by UCLA movement 
disorder specialists at a local clinic, and 119 cases were excluded after examination as they were 
classified as Parkinsonism or not having idiopathic PD. After excluding the cases that provided 
incomplete information for analyses, 472 cases remained for analyses. Thus, from the two waves 
of recruitment, we have assembled 832 PD cases for analyses. 
 Population controls in the first PEG study were recruited from 2001 to 2007 by mail or phone 
for a screening that established that they did not have PD; they also lived in one of the three 
counties and in California for at last five years or more, and were 35+ years of age. A total of 1,212 
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potential population controls were eligibility screened, and 755 were eligible after excluding those 
who were too young, terminally ill, or lived mostly outside the study area. We enrolled 521 controls, 
and 389 controls provided information that was needed for analyses. The second wave of 
population controls was recruited as part of the Center for Gene-Environment Research in 
Parkinson's Disease (CGEP) study. We randomly selected residential parcels from the tax-collector 
record and visited five homes around the index parcel in-person to recruit eligible controls. After 
excluding controls who were ineligible and provided incomplete information, 428 controls were 
enrolled. Thus, a total of 817 population controls are available for the analyses. 
2.2 Data Collection 
Study participants at baseline provided information about diagnoses of depression and anxiety 
including their age at first diagnosis as well as psychotropic medication use for depression and/or 
anxiety; specifically type (name), amount (pills per day/week), duration (weeks or months), and 
age at first and last use of each medication were reported. Interviewers were blinded to the subject’s 
PD status as this information together with demographic and lifestyle characteristics were 
collected by telephone. 
2.3 Organophosphate Exposure Assessment 
Ambient Pesticide Exposures 
 Ambient residential pesticide exposure and ambient workplace pesticide exposure were 
estimated with a geographic information system (GIS) – based computer model. This model 
combined data from California state-mandated pesticide exposure reports (CA PUR) (27) that 
include information on agricultural pesticide applications and the date, location, amount applied, 
with land-use surveys from California’s Department of Water Resources (28) and geocoded 
lifetime residential and occupational address histories of participants. Pounds of chemical per acre 
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per year within a 500m radius surrounding each address were estimated. We then calculate yearly 
average exposures for each chemical from 1974 to the date that is ten years before the date of PD 
diagnosis for cases or ten years before the date of interview for controls by summing years specific 
averages divided by the total number of years in the relevant period. Simple imputation was used 
if the geocoded location information for a participant in any given year was missing. Based on the 
information from CDPR and the pesticide action network (PAN) pesticide database, data from the 
PUR system showed that members of the study population were potentially exposed to some 40 
chemicals classified as OPs (29). We dichotomized into “frequent” versus “occasional” exposures 
based on the OPs poundage per acres being at or above versus below the median in exposed control. 
2.4 Statistical Analysis 
 Logistic regression was used to estimate the odds ratios (OR) and 95% confidence intervals 
(CI) for depression and anxiety and PD as the ratio of odds for PD among those with pre-existing 
depression or anxiety versus those without these psychiatric diagnoses or treatments for the 
disorders. We also adjusted the ORs to address potential confounding by gender, age at 
diagnosis/interview (< 55 years, 55 to 65 years, > 65 years), race (Caucasian, Latino, other), pack-
years of smoking (0, 0+ to 9, 10 to 39, 40+), and years of formal education (< 12 years, 12 years, 
13 to 16 years, > 16 years).  
We used two outcome measures: depression/anxiety diagnosis only and depression/anxiety 
diagnosis plus treatment. We also ensured that the age of depression and/or anxiety diagnosis 
and/or medication use was prior to the index date (for cases PD diagnosis, for controls time of 
interview). We then excluded the cases and controls whose depression and/or anxiety diagnosis 
and/or medication use had occurred more than 2, 5, 10, and 20 years before the index age in order 
to analyze depression and/or anxiety that had first occurred within the past 2, 5, 10, and 20 years. 
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We also stratified all analyses by gender.  
Finally, we investigated whether 1) gender modifies the association between 
depression/anxiety and PD and 2) OPs modify the association of depression and PD (by gender), 
using stratified analyses and introducing product terms into logistic models to assess multiplicative 
interactions. All analyses in this study were conducted in SAS version 9.4. 
 
3. Result 
Study participants were predominantly Caucasian (76.6% in cases vs. 69.3% in controls) and 
did not have a family history of PD (83.9% in cases vs. 92.0% in controls). Cases completed less 
years of education (> 12 years: 60.7% of cases vs. 64.5% of controls), smoked less per year (cases 
9.4 packs per year vs. controls 12.3 packs per year). Cases were slightly older than controls (67.7 
years in cases vs. 65.9 years in controls), more frequently male (63.1% of cases vs. 46.3% of 
controls), more likely to have received a depression and/or anxiety diagnosis and use depression 
and/or anxiety medications (44.1% cases vs. 30.0% controls) (Table 1). 
The odds of being diagnosed with depression and/or anxiety before the index date was higher 
in PD cases (OR = 1.61, 95% CI = 1.28-2.04), especially those also reporting to have been treated 
(OR = 1.73, 95% CI = 1.37-2.18). Males with PD had higher odds of a depression/anxiety 
diagnosis (OR = 2.12, 95% CI = 1.50-3.00) whether or not treated and the closer the diagnosis of 
depression and/or anxiety was made to a PD diagnosis, the stronger the effect estimates became. 
Females with PD had only a slightly higher odds of having been diagnosed with depression/anxiety 
in general (OR = 1.23, 95% CI = 0.88-1.73), but for those medicated the effect size was stronger 
(OR = 1.41, 95% CI = 1.01-1.96), and again associations were much stronger when the age of a 
depression/anxiety diagnosis was close in time to a PD diagnosis (Table 2). 
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We formally investigated effect measure modification by sex for a depression/anxiety 
diagnosis and PD, and we saw some evidence as the p-value for interaction was 0.016 (Table 3). 
Finally, we also assessed effect measure modification with ambient OPs exposures, both at 
the residence and/or the workplace to investigate whether OP exposure modified the relationship 
between depression/anxiety and in males and females’ PD (Table 4). None of the interaction test 
p-values were not formally statistically significant; however, the ORs we estimated for the joint 
effects were higher than the sum of the main effects for a depression/anxiety diagnosis and OP 
pesticide exposures alone minus the effects for the reference group. In males, the joint effect of 
ambient workplace OPs exposure and depression and/or anxiety was especially high (ORFrequent 
exposure + Received depression and/or anxiety diagnosis = 5.00, 95%CI = 2.54-9.87). 
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Table 1 
Demographic characteristic and risk factor distribution of California Central valley Parkinson’s study subjects. 
 Case (n=832) 
n (%) / Mean (SD) 
Control (n=817) 
n (%) / Mean (SD) 
Age 67.74 (10.59) 65.92 (11.71) 
Sex   
  Female 307 (36.9%) 439 (53.7%) 
  Male 525 (63.1%) 378 (46.3%) 
1st Degree Relative with PD 134 (16.1%) 65 (8.0%) 
(missing=13) 
Race   
  White 637 (76.6%) 566 (69.3%) 
  Black 5 (0.6%) 26 (3.2%) 
  Latino 138 (16.6%) 155 (19.00%) 
  Asian 22 (2.6%) 25 (3.1%) 
  Native American 29 (3.5%) 43 (5.3%) 
  Missing 1 (0.1%) 2 (0.2%) 
   
Education   
  < 12 years 140 (16.84%) 119 (14.6%) 
  = 12 years 187 (22.5%) 171 (20.9%) 
  > 12 years 505 (60.7%) 527 (64.5%) 
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Table 1 (Continued) 
Demographic characteristic and risk factor distribution of California Central valley Parkinson’s study subjects. 
 Case (n=832) 
n (%) / Mean (SD) 
Control (n=817) 
n (%) / Mean (SD) 
Education (continued)   
  < 12 years 140 (16.8%) 119 (14.6%) 
  = 12 years 187 (22.5%) 171 (20.9%) 
  13 to 16 years 319 (38.3%) 333 (40.8%) 
  >16 years 186 (22.4%) 194 (23.8%) 
Cigarette (pack-year) 9.43 (19.55) 12.28 (20.12) 
  0 457 (54.9%) 397 (48.6%) 
  0+ to 9 169 (20.3%) 144 (17.6%) 
  10 to 39 143 (17.2%) 185 (22.6%) 
  40+ 63 (7.6%) 91 (11.1%) 
Depression and/or anxiety diagnosis   
  Never received 514 (61.8%) 598 (73.2%) 
  Ever received 318 (38.2%) 219 (26.8%) 
Depression and/or anxiety diagnosis diagnosed within 10 years prior to index date a b   
  Never received 514 (81.2%) 598 (86.3%) 
  Ever received 119 (18.8%) 95 (13.7%) 
   
Never received depression and anxiety diagnosis 514 (61.8%) 598 (73.2%) 
Received anxiety diagnosis and never received depression diagnosis  67 (8.1%) 33 (4.0%) 
Received depression diagnosis and never received anxiety diagnosis 108 (13.00%) 88 (10.8%) 
Received depression and anxiety diagnosis 143 (17.2%) 98 (12.0%) 
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Table 1 (Continued) 
Demographic characteristic and risk factor distribution of California Central valley Parkinson’s study subjects. 
 Case (n=832) 
n (%) / Mean (SD) 
Control (n=817) 
n (%) / Mean (SD) 
Never received depression and anxiety diagnosis within 10 years prior to index date b 514 (81.2%) 598 (86.3%) 
Received anxiety and never received depression diagnosis within 10 years prior to index date b 22 (3.5%) 13 (1.9%) 
Received depression and never received anxiety diagnosis within 10 years prior to index date b 47 (7.4%) 38 (5.5%) 
Received depression and anxiety diagnosis within 10 years prior to index date b 50 (7.9%) 44 (6.4%) 
   
Diagnosis + no medication use 63 (19.8%) 41 (18.7%) 
Diagnosis + medication use 255 (80.2%) 178 (81.3%) 
   
Depression and/or anxiety diagnosis and/or medical use   
Never diagnosis and/or medication use 465 (55.9%) 572 (70.0%) 
Ever diagnosis and/or medication use 367 (44.1%) 245 (30.0%) 
   
Depression and/or anxiety diagnosis and/or medication use within 10 years prior to index age c   
Never diagnosis and/or medication use 465 (77.8%) 572 (84.5%) 
Ever diagnosis and/or medication use 133 (22.2%) 105 (15.5%) 
a Index date: age at PD diagnosis for cases; age at interview for controls.  
b 633 cases and 693 controls diagnosed as depression and/or anxiety within 10 years prior to index date 
c 598 cases and 677 controls diagnosed as depression and/or anxiety and/or medication use within 10 years prior to index date 
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Table 2 
Association between psychiatric disorders diagnosed and/or medication history before Parkinson’s disease and Parkinson’s disease 
diagnosis. 
 Cases without 
depression 
and/or anxiety 
Cases with 
depression 
and/or anxiety 
 Controls 
without 
depression 
and/or anxiety 
Controls with 
depression 
and/or anxiety 
 Cases/controls 
n n (%)  n n (%)  ORa 95%CI 
All cases         
 Diagnosis model 514   598     
Depression and/or anxiety within 2 years prior to index date b  44 (7.9%)   25 (4.0 %)  2.41  (1.41, 4.09) 
  Depression and/or anxiety within 5 years prior to index date  83 (13.9%)   54 (8.3%)  2.14 (1.46, 3.14) 
  Depression and/or anxiety within 10 years prior to index date  119 (18.8%)   95 (13.7%)  1.72 (1.26, 2.36) 
  Depression and/or anxiety within 20 years prior to index date  164 (24.2%)   145 (19.5%)  1.57 (1.20, 2.05) 
Depression and/or anxiety any time prior to index date  238 (31.7%)   211 (26.1%)  1.61 (1.28, 2.04) 
         
 Diagnosis + Medication Model 465   572     
  Depression and/or anxiety within 2 years prior to index date  50 (9.7%)   30 (5.0%)  2.32 (1.42, 3.80) 
  Depression and/or anxiety within 5 years prior to index date  93 (16.7%)   62 (9.8%)  2.19 (1.52, 3.15) 
  Depression and/or anxiety within 10 years prior to index date  133 (22.2%)   105 (15.5%)  1.88 (1.39, 2.55) 
  Depression and/or anxiety within 20 years prior to index date  186 (28.6%)   164 (22.3%)  1.69 (1.30, 2.19) 
Depression and/or anxiety any time prior to index date  266 (36.4%)   237 (29.3%)  1.73 (1.37, 2.18) 
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Table 2 (Continued) 
Association between psychiatric disorders diagnosed and/or medication history before Parkinson’s disease and Parkinson’s disease 
diagnosis. 
 Cases without 
depression 
and/or anxiety 
Cases with 
depression 
and/or anxiety 
 Controls 
without 
depression 
and/or anxiety 
Controls with 
depression 
and/or anxiety 
 Cases/controls 
n n (%)  n n (%)  ORa 95%CI 
Sex         
Male only         
 Diagnosis model 339   311     
  Depression and/or anxiety within 2 years prior to index date  30 (8.1%)   11 (3.4%)  2.98 (1.42, 6.26) 
  Depression and/or anxiety within 5 years prior to index date  53 (13.5%)   20 (6.0%)  2.92 (1.65, 5.18) 
  Depression and/or anxiety within 10 years prior to index date  80 (19.1%)   33 (9.6%)  2.52 (1.60, 3.97) 
  Depression and/or anxiety within 20 years prior to index date  106 (23.8%)   47 (13.1%)  2.27 (1.53, 3.35) 
Depression and/or anxiety any time prior to index date  137 (28.8%)   62 (16.6%)  2.12 (1.50, 3.00) 
         
 Diagnosis + Medication Model 313   302     
  Depression and/or anxiety within 2 years prior to index date  34 (9.8%)   15 (4.7%)  2.54 (1.32, 4.88) 
  Depression and/or anxiety within 5 years prior to index date  56 (15.2%)   25 (7.7%)  2.49 (1.47, 4.21) 
  Depression and/or anxiety within 10 years prior to index date  84 (21.2%)   36 (10.7%)  2.53 (1.63, 3.93) 
  Depression and/or anxiety within 20 years prior to index date  116 (27.0%)   51 (14.5%)  2.38 (1.63, 3.48) 
Depression and/or anxiety any time prior to index date  148 (32.1%)   71 (19.0%)  2.11 (1.52, 2.94) 
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Table 2 (Continued) 
Association between psychiatric disorders diagnosed and/or medication history before Parkinson’s disease and Parkinson’s disease 
diagnosis. 
 Cases without 
depression 
and/or anxiety 
Cases with 
depression 
and/or anxiety 
 Controls 
without 
depression 
and/or anxiety 
Controls with 
depression 
and/or anxiety 
 Cases/controls 
n n (%)  n n (%)  ORa 95%CI 
Female only         
 Diagnosis model 175   287     
  Depression and/or anxiety within 2 years prior to index date  14 (7.4%)   14 (4.7%)  1.76 (0.78, 3.97) 
  Depression and/or anxiety within 5 years prior to index date  30 (14.6%)   34 (10.6%)  1.50 (0.85, 2.63) 
  Depression and/or anxiety within 10 years prior to index date  39 (18.2%)   62 (17.8%)  1.13 (0.70, 1.82) 
  Depression and/or anxiety within 20 years prior to index date  58 (24.9%)   98 (25.5%)  1.02 (0.68, 1.53) 
Depression and/or anxiety any time prior to index date  101 (36.6%)   149 (34.2%)  1.23 (0.88, 1.73) 
         
 Diagnosis + Medication Model 152   270     
  Depression and/or anxiety within 2 years prior to index date  16 (9.5%)   15 (5.3%)  2.07 (0.95, 4.52) 
  Depression and/or anxiety within 5 years prior to index date  37 (19.6%)   37 (12.1%)  1.85 (1.08, 3.16) 
  Depression and/or anxiety within 10 years prior to index date  49 (24.4%)   69 (20.4%)  1.37 (0.87, 2.14) 
  Depression and/or anxiety within 20 years prior to index date  70 (31.5%)   113 (29.5%)  1.14 (0.77, 1.68) 
  Depression and/or anxiety any time prior to index date  118 (43.7%)   166 (38.1%)  1.41 (1.01, 1.96) 
a ORs are adjusted for sex, age, race, pack-years of smoking, and education. 
b Index date: age at PD diagnosis for cases; age at interview for controls. 
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Table 3 
Interaction, main, and joint effect estimates for receiving depression and anxiety diagnosis and sex in association with PD. 
 Never received depression and anxiety diagnosis  Received depression and/or anxiety diagnosis p for 
interaction 
 Case/controls Adj ORa(95% CI)  Case/controls Adj ORa(95% CI)  
Sex 
Female 175/287 1.00 (reference)  101/149 1.22 (0.88, 1.69)  
Male 339/311 2.07 (1.60, 2.67)  137/62 4.53 (3.12, 6.56) 0.016* 
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Table 4 
Interaction, main, and joint effect estimates for receiving depression and anxiety diagnosis and OPs exposure in association with PD 
stratified by sex. 
 Never received depression and anxiety 
diagnosis 
 Received depression and/or anxiety 
diagnosis 
p for 
interaction 
OP Exposure Category Case/controls Adj ORa(95% CI)  Case/controls Adj ORa(95% CI)  
Sex 
Male 
Ambient OP exposure 
Occasional use 183/197 1.00 (reference)  73/39 2.12 (1.35, 3.32)  
Frequent use 155/113 1.56 (1.12, 2.16)  64/23 3.34 (1.94, 5.75) 0.972 
       
Ambient residential OP use 
Occasional use 218/218 1.00 (reference)  86/47 1.86 (1.23, 2.82)  
Frequent use 120/92 1.28 (0.91, 1.81)  51/15 3.76 (2.01, 7.07) 0.253 
       
Ambient workplace OP use 
Occasional use 218/229 1.00 (reference)  84/50 1.85 (1.24, 2.79)  
Frequent use 120/81 1.57 (1.11, 2.23)  53/12 5.00 (2.54, 9.87) 0.196 
 
Female 
Ambient OP exposure 
Occasional use 110/188 1.00 (reference)  60/91 1.24 (0.81, 1.89)  
Frequent use 65/99 1.26 (0.83, 1.91)  41/57 1.52 (0.91, 2.51) 0.945 
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Table 4 (Continued) 
Interaction, main, and joint effect estimates for receiving depression and anxiety diagnosis and OPs exposure in association with PD 
stratified by sex. 
 Never received depression and anxiety 
diagnosis 
 Received depression and/or anxiety 
diagnosis 
p for 
interaction 
OP Exposure Category Case/controls Adj ORa(95% CI)  Case/controls Adj ORa(95% CI)  
 
Ambient residential OP use 
Occasional use 115/209 1.00 (reference)  63/96 1.32 (0.87, 2.01)  
Frequent use 60/78 1.58 (1.02, 2.44)  38/52 1.62 (0.96, 2.71) 0.468 
       
Ambient workplace OP use 
Occasional use 130/222 1.00 (reference)  74/115 1.22 (0.83, 1.80)  
Frequent use 45/65 1.31 (0.82, 2.09)  27/33 1.66 (0.92, 3.00) 0.929 
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4. Discussion 
 We confirmed our previous findings that depression/anxiety - especially among those who 
were treated for these mood disorders - increased the risk of PD, most strongly in men. Furthermore, 
as we also saw before, estimate effect sizes tended to increase as a first depression/anxiety 
diagnosis was made more closely in time to the diagnosis of PD. This provides further supports 
for the hypothesis that depression and anxiety are early symptoms that occur in the prodromal 
phase of PD, consistent with previous studies (24, 30). For women with PD, the risk estimates 
were generally smaller and not always formally statistically significant, most likely due to a very 
high baseline rate of depression/anxiety we observed among female controls. As expected, 
requiring psychiatric treatment, however, increased the specificity of these diagnoses among 
women.  
 It is well-known that males have a higher risk of developing PD than females (31-33) while 
females are more often diagnosed with depression (34). Whether the later represents a bias among 
medical providers who might be more inclined to recognize and diagnose depression in women 
than men or gender-specific healthcare-seeking behaviors or true gender differences in such 
disorders in the communities we studied is unclear. 
We included only patients who had depression prior to PD diagnosis to exclude anyone with 
reactive depression that might not be due to changes in brain circuitry related to PD (10). 
Previously research indicated that PD patients are at least two times more likely to suffer from 
depression in the prodromal years before PD is diagnosed; this has been interpreted as indicative 
of a neurodegenerative process that causes mood disorders before motor symptoms appear (9). 
This process or the risk factors that contribute to it might be different than those that affect PD 
patients who do not develop depression prodromally. Also, depression has not been a common 
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feature in familial PD, and genetic factors do not seem to play any major role in the origin of 
depression in PD (9). Thus, here we explored whether environmental risk factors known to be 
associated with PD in general and possibly also with depression idependently in population studies 
also affect the risk of PD with depression more strongly. We here focused on OP exposures as they 
have been associated with depression among farmers (17). Also, neuroimaging studies that 
compared PD patients with depression and without depression found abnormal activity and inverse 
correlations between depression and brain volumes in the prefrontal and limbic regions in PD 
patients with but not without depression (35), and OP poisoning has been shown to result in neural 
loss in cholinergic areas of the brain such as the basal forebrain and the limbic system (36). 
A recent review of imaging studies (35) concluded that depression in PD likely does not just 
result from a single brain region or neurotransmitter system but rather may involve the 
dysregulation of cortico-limbic networks in addition to the nigrostriatal pathway. 
 The PEG study cases and controls live and work in predominantly agricultural communities 
with a high prevalence of pesticide exposure and exposure including to OP pesticides. Previous 
studies have shown that OPs exposures might increase the risk of PD (37-40). OPs exposures are 
known to inhibit acetylcholinesterase, and especially among those in the population who 
constitutively have slow PON1 activity, the accumulation of toxic metabolites and free oxygen 
radicals can cause damage to the nervous system. That is elevated acetylcholine levels and 
resulting impairments of the dopamine and acetylcholine balance in the striatum may increase the 
risk of both neuropsychiatric and PD (17, 41). OPs exposure can also inhibit DRN, which secrets 
serotonin, and the inhibition of DRN is related to depression in PD patients (21, 42). Thus, we 
were interested in how OP exposures may affect both the onset of depression and anxiety during 
the prodromal stages of PD as well as of PD itself. 
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A study using Taiwan National Health Insurance (NHI) program investigated interactions 
between OPs or carbamate poisoning defined by International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes (ICD-9-CM code: 989.3) and comorbidities 
including depression, stroke, dementia, or psychosis with PD (37). They reported that the PD risk 
for those with comorbidities including depression was higher among individuals with a diagnosis 
of OPs or carbamate poisoning, even though the interaction was not formally statistically 
significant. We also found a higher joint effect of OPs exposure and depression/anxiety, suggesting 
that a depression/anxiety diagnosis prodromal to PD onset amongst those who are chronically OPs 
exposed increases the risk of developing PD more strongly than either factor alone, especially for 
males. 
 As our study enrolled a very large number of PD cases, it allowed us to examine effect 
measure modification relatively efficiently and to distinguish between male and female PD cases. 
Misclassification of PD diagnosis in PEG is limited because PD cases were recruited according to 
stringent diagnostic criteria and clinically evaluated by a UCLA movement disorder specialist 
often more than once during follow-up of the cases over many years. However, this study still has 
several limitations. First, selection bias may be an issue if depression history affects participation 
rates. Controls who have a depression and anxiety diagnosis may have been less willing to actively 
participate in this study, especially males. We also found that among our female controls, there 
was a very high lifetime prevalence of depression/anxiety of almost 35% similar to female PD 
cases. Because this information was obtained by self-report retrospectively, over- or 
underreporting may affect these estimates. Furthermore, some misclassification may be due to the 
timing of the depression/anxiety diagnoses, but studies have shown that self-reported age at onset 
of depression is fairly reliable (43, 44). We assess ambient pesticide exposure with the GIS method 
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using the CA-PUR record. Thus, recall bias may not be an issue because the assessment of ambient 
pesticide is record-based. However, we do not consider geographic features and wind patterns that 
may cause exposure misclassification. 
For PD patients, the consequences of depression/anxiety in PD might be depressed mood, 
loss of interest and concentration, and anhedonia. The quality of life and cognitive domains for PD 
patients may also be negatively impacted by depression/anxiety (9, 45).  
 In summary, our results support an early depression/anxiety phenotype that emerges as an 
early symptom during the prodromal phase of PD, especially in males, and this phenotype seems 
to be more strongly related to toxicant exposures, in this case OP pesticide exposures. Whether 
this phenotype is also related to differences in progression rates and overall severity in males needs 
to be explored in future studies. 
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